YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy

YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy

Introduction: Prostate cancer is the second leading cause of cancer death among men in the United States. Castration-Resistant Prostate Cancer (CRPC) often develops resistance to androgen deprivation therapy. Resistance in CRPC is often driven by AR variants and glucocorticoid receptor (GR). Thus, d...

Full description

Bibliographic Details
Main Authors: Wing Lam, Mohammad Arammash, Wei Cai, Fulan Guan, Zaoli Jiang, Shwu-Huey Liu, Peikwen Cheng, Yung-Chi Cheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Pharmacology
Subjects:
YIV-818-A
AR
GR
prostate cancer
apalutamide
darolutamide
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1244655/full

Similar Items

Similar Items